Intense Radiation + Chemotherapy for Lung Cancer
Recruiting at 6 trial locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Phase 1 & 2
Waitlist Available
Sponsor: Proton Collaborative Group
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over a shorter period of time.
Research Team
BH
Brad Hoppe, MD
Principal Investigator
Proton Collaborative Group
Eligibility Criteria
This trial is for adults with stage II-III non-small cell lung cancer who can't have surgery. They should be in good physical condition, not pregnant, willing to use contraception, and haven't lost a lot of weight recently. No prior chest radiation or evidence of cancer spread far from the lung is allowed.Inclusion Criteria
Your lab test results must be from within the 4 weeks before you join the study.
Your white blood cell count must be higher than 1,800 cells/mm3.
You have at least 100,000 platelets per cubic millimeter of blood.
See 11 more
Exclusion Criteria
I have had radiation therapy to my chest area before.
I have lost more than 10% of my weight without trying in the last month.
I am not pregnant or breastfeeding and willing to use contraception during and for 12 months after the study.
See 1 more
Treatment Details
Interventions
- Concurrent Chemotherapy (Chemotherapy)
- Hypofractionated Proton Therapy (Proton Beam Therapy)
Trial OverviewThe study tests if giving higher daily doses of proton radiation therapy over fewer days (hypofractionation) combined with standard chemotherapy works better for treating non-small cell lung cancer than current methods.
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Proton Radiotherapy with ChemotherapyExperimental Treatment1 Intervention
Concurrent Chemotherapy is already approved in Canada for the following indications:
Approved in Canada as Concurrent Chemotherapy for:
- Locally advanced cervical cancer
Find a Clinic Near You
Who Is Running the Clinical Trial?
Proton Collaborative Group
Lead Sponsor
Trials
10
Recruited
41,100+